Dystonia & Parkinsonism Panel

New York
Approved


Genes

ADAR, ADCY5, AFG3L2, ANO3, APTX, ARSA, ATM, ATP13A2, ATP1A2, ATP1A3, ATP6AP2, ATP7B, BCAP31, C19orf12, CACNA1A, CACNA1B, CHCHD2, COASY, CP, CYP27A1, DCAF17, DCTN1, DDC, DLAT, DNAJC12, DNAJC5, DNAJC6, ECHS1, FA2H, FBXO7, FITM2, FTL, FUCA1, GBA, GCDH, GCH1, GLRA1, GNAL, GNAO1, HEXA, HPCA, HPRT1, KCNJ6, KCNMA1, KCTD17, KMT2B, LRRK2, MAPT, MARS2, MCOLN1, MECR, MRE11, NKX2-1, NPC1, NPC2, NUBPL, NUS1, PANK2, PARK7, PDGFB, PDGFRB, PINK1, PLA2G6, PNKD, PNKP, POLG, POLR3B, PRKN, PRKRA, PRRT2, PTS, RAB39B, SCP2, SERAC1, SGCE, SLC16A2, SLC19A3, SLC20A2, SLC2A1, SLC30A10, SLC6A3, SMPD1, SNCA, SPAST, SPR, SQSTM1, SUCLA2, SYNJ1, TH, THAP1, TIMM8A, TOR1A, TOR1AIP1, TPK1, TPP1, TRAPPC11, TUBB4A, TWNK, VPS13A, VPS35, WDR45, XPR1, ZFYVE26

Conditions

  • Primary Familial Brain Calcification (PFBC)
  • Myoclonus dystonia
  • Paroxysmal dyskinesia
  • Torsion dystonia
  • Combined dystonia
  • Dystonia-deafness syndromes
  • Dopa-responsive parkinsonism
  • Atypical parkinsonism
  • Progressive Supranuclear Palsy (PSP)
  • Dopa-Responsive Dystonia
  • Wilson Disease
  • Neurodegeneration with Brain Iron Accumulation (NBIA)
  • Dystonia
  • Parkinson Disease
  • Parkinsonism
  • Movement Disorder
  • Tremors
  • Bradykinesia

Clinical Utility

  • Molecular confirmation of a clinical diagnosis
  • Identification of at-risk family members
  • Assist with treatment/ management decisions
  • Recurrence risk assessment

Lab Method

  • Next-Gen Sequencing
  • Deletion/Duplication Analysis
  • Capillary Sequencing

Test Code

T402

CPT Codes*

81404x3, 81405x6, 81406x13, 81408x2, 81185x1, 81479x1

ABN Required

No

Turnaround Time**

4 weeks

Preferred Specimen

2-5 mL Blood - Lavender Top Tube

Alternative Specimen

Buccal Swabs

*The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

**Turnaround times are estimates and begin once the sample(s) begin processing at the GeneDx lab and could be extended in situations outside GeneDx’s control.